-
公开(公告)号:US20190212317A1
公开(公告)日:2019-07-11
申请号:US15830812
申请日:2017-12-04
发明人: Nigel CLARKE
CPC分类号: G01N33/15 , G01N30/7233 , G01N33/48 , G01N33/49 , G01N33/94 , H01J49/00 , H01J49/0031 , H01J49/004 , H01J49/0045 , H01J49/10 , Y10T436/17 , Y10T436/24 , Y10T436/25125 , Y10T436/25375
摘要: Provided are methods for determining the amount of tamoxifen and its metabolites in a sample by mass spectrometry. In some aspects, the methods provided herein determine the amount of norendoxifen. In some aspects, the methods provided herein determine the amount of norendoxifen and tamoxifen. In some aspects, the methods provided herein determine the amount of norendoxifen and other tamoxifen metabolites. In some aspects, the methods provided herein determine the amount of tamoxifen, norendoxifen, and other tamoxifen metabolites.
-
2.
公开(公告)号:US20190202915A1
公开(公告)日:2019-07-04
申请号:US16314474
申请日:2017-06-30
申请人: TOHOKU UNIVERSITY
发明人: Taku FUJIMURA
CPC分类号: C07K16/2818 , A61P35/00 , C07K14/52 , C07K14/705 , C07K16/24 , C07K16/28 , C07K16/2827 , G01N33/15 , G01N33/53 , G01N33/68 , G01N33/6893 , G01N2333/522 , G01N2333/70596 , G01N2800/52
摘要: The present invention provides a novel method of obtaining data for predicting the onset of an adverse event due to administration of at least one antibody drug selected from an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA4 antibody, and an antigen-binding fragment thereof, or a novel method of predicting the onset of the adverse event. More specifically, the present invention provides a method of obtaining data for predicting the onset of an adverse event or a method of predicting the onset of the adverse event, comprising measuring a level of at least one marker selected from sCD163 and CXCL5 in a biological sample collected from a subject administered the antibody drug.
-
公开(公告)号:US20190194298A1
公开(公告)日:2019-06-27
申请号:US16223463
申请日:2018-12-18
发明人: Shunhai Wang
CPC分类号: C07K16/00 , B01D15/305 , C07K16/065 , C07K2317/14 , C07K2317/41 , C07K2317/50 , C07K2317/515 , C07K2317/55 , G01N33/15 , G01N2030/027 , G01N2030/8831
摘要: Systems and methods for characterizing low molecular weight (LMW) protein drug product impurities are provided. One embodiment uses hydrophilic interaction chromatography (HILIC) coupled to mass spectrometry analysis. After removal of the N-linked glycans from the protein drug product, for example an antibody drug product, the elution of LMW impurities from the HILIC column was determined by the size of the molecular weight species. In some embodiments, the HILIC separation is performed under denaturing conditions, making the detection of LMW forms using this method highly comparable to both SDS-PAGE and CE-SDS methods. LMW drug product impurities include, but are not limited to light chain, half antibody, H2L, H2, HL, HC, peptide backbone-truncated species, and combinations thereof.
-
公开(公告)号:US20190025203A1
公开(公告)日:2019-01-24
申请号:US15859378
申请日:2017-12-30
申请人: Serguei Koulikov
发明人: Serguei Koulikov
IPC分类号: G01N21/39 , G01N21/27 , G01N21/3504 , G01J3/42
CPC分类号: G01N21/3504 , G01J3/42 , G01N21/27 , G01N21/31 , G01N21/39 , G01N21/716 , G01N33/15 , G01N2021/1704 , G01N2021/1748 , G01N2021/399 , G01N2201/0612
摘要: The present invention provides a system for measuring concentrations of trace gases in gas mixtures using the absorption spectroscopy method. The system comprising: a resonant optical cavity, a continuous-wave stepwise tunable external cavity laser having a DFB laser as a gain media; a detector system for measuring an absorption of laser light by the gas in the resonant optical cavity, wherein the roundtrip optical cavity length of the external cavity laser are the roundtrip optical cavity length of the resonant cavity are close
-
公开(公告)号:US20180296098A1
公开(公告)日:2018-10-18
申请号:US16016649
申请日:2018-06-24
申请人: OMNI MEDSCI, INC.
发明人: Mohammed N. ISLAM
IPC分类号: A61B5/00 , G01J3/28 , A61B5/145 , A61B5/1455 , G01N21/39 , G06F19/00 , G01N21/88 , G16H40/67 , G01J3/02 , G01J3/10 , G01J3/14 , G01N33/02 , G01N21/359 , G01N21/3563 , G01N21/35 , G01N33/49 , G01N33/44 , G01N33/15 , G01J3/453 , G01J3/42 , G01J3/18 , G01J3/12 , G01M3/38 , G01N21/85 , G01N21/95 , H01S3/00 , H01S3/30 , H01S3/067
CPC分类号: A61B5/0088 , A61B5/0013 , A61B5/0022 , A61B5/0024 , A61B5/0075 , A61B5/0086 , A61B5/14532 , A61B5/14546 , A61B5/1455 , A61B5/4547 , A61B5/6801 , A61B5/7203 , A61B5/7257 , A61B5/7405 , A61B5/742 , A61B2562/0233 , A61B2562/0238 , A61B2562/146 , A61B2576/02 , A61C1/0046 , A61C19/04 , G01J3/0218 , G01J3/108 , G01J3/14 , G01J3/1838 , G01J3/28 , G01J3/2823 , G01J3/42 , G01J3/453 , G01J2003/104 , G01J2003/1208 , G01J2003/2826 , G01M3/38 , G01N21/35 , G01N21/3563 , G01N21/359 , G01N21/39 , G01N21/85 , G01N21/88 , G01N21/9508 , G01N33/02 , G01N33/025 , G01N33/15 , G01N33/442 , G01N33/49 , G01N2021/3595 , G01N2021/399 , G01N2201/061 , G01N2201/06113 , G01N2201/062 , G01N2201/08 , G01N2201/12 , G01N2201/129 , G06F19/00 , G16H40/67 , H01S3/0092 , H01S3/06758 , H01S3/302
摘要: A wearable device includes a measurement device adapted to be placed on a wrist or ear having a light source with LEDs to measure physiological parameters. The measurement device generates an optical beam having a near infrared wavelength between 700-2500 nanometers by modulating the LEDs, and lenses to deliver the beam to tissue, which reflects the beam to a receiver having spectral filters in front of spatially separated detectors coupled to analog to digital converters that generate at least two receiver outputs. Signal-to-noise ratio of the beam reflected from the tissue is improved by comparing the receiver outputs, and by increasing light intensity from the LEDs. The receiver is synchronized to the modulation of the LEDs and uses a lock-in technique that detects the modulation frequency. The measurement device generates an output signal representing a non-invasive measurement on blood within the tissue.
-
公开(公告)号:US20180246023A1
公开(公告)日:2018-08-30
申请号:US15756896
申请日:2016-08-26
申请人: ERWEKA GmbH
CPC分类号: G01N3/40 , G01B5/08 , G01N33/00 , G01N33/15 , G01N2033/0077 , G01N2203/0019 , G01N2203/0076 , G01N2203/0085 , G01N2203/0087 , G01N2203/0206
摘要: A device and a method for testing tablets are disclosed. The device for testing tablets includes a test chamber, which has a crusher jaw and, lying opposite the latter, a counter-jaw. The device has a movable sheet metal strip, which is designed to position a tablet for testing. The longitudinal axis of the movable sheet metal strip is at an angle of less than 90° to the longitudinal axis of the direction of movement of the crusher jaw, and the direction of movement of the sheet metal strip corresponds to the longitudinal axis of the sheet metal strip.
-
公开(公告)号:US10007920B2
公开(公告)日:2018-06-26
申请号:US14650244
申请日:2013-12-06
申请人: The United States of America, as represented by the Secretary, Department of Health & Human Services
发明人: Nicola Ranieri , Mark R. Witkowski , Mike D. Green
CPC分类号: G06Q30/0185 , G01N21/9508 , G01N33/15 , G06K9/2018 , G06Q50/22 , H04N5/2256
摘要: One aspect of the invention provides a device for detecting a counterfeit product. The device includes: a plurality of light sources configured to emit light at a plurality of different wavelengths onto an object potentially including a suspect product; at least one image acquisition device adapted and configured to acquire image data; and a communications interface adapted and configured to transmit the image data to a computing device selected from the group consisting of: a tablet computer and a smartphone.
-
公开(公告)号:US20180142294A1
公开(公告)日:2018-05-24
申请号:US15800768
申请日:2017-11-01
申请人: APDN (B.V.I.) INC.
IPC分类号: C12Q1/6876 , G01N33/15 , G09F3/02
CPC分类号: C12Q1/6876 , C12Q1/68 , C12Q1/686 , G01N33/15 , G09F3/02 , G09F2003/0277 , C12Q2563/173 , C12Q2563/185
摘要: Provided is a method of authenticating an active pharmaceutical ingredient (API). The method includes providing an API or an API component and adding a nucleic acid marker having a nucleic acid marker sequence to produce a marked API or a marked API component. The presence of the nucleic acid marker is detected in the sample and the authenticity of the API is thereby determined according to whether the pharmaceutical product includes marked API or the marked API component.
-
公开(公告)号:US20180128752A1
公开(公告)日:2018-05-10
申请号:US15805246
申请日:2017-11-07
申请人: Sandoz Canada Inc.
CPC分类号: G01N21/94 , G01N1/34 , G01N1/4044 , G01N21/49 , G01N21/8803 , G01N33/15 , G01N2015/0053 , G01N2015/0687 , G01N2015/0693
摘要: The present invention relates to novel methods for detection of the presence or absence of particulate matter in an opaque fluid, novel methods for inspection of an opaque fluid for the presence or absence of particulate matter therein, and use of such methods in the manufacture of an opaque fluid. Methods comprise clarifying the fluid to enable detection of the presence or absence of particulate matter therein or to enable inspection of the opaque fluid for the presence or absence of particulate matter therein.
-
公开(公告)号:US20180100177A1
公开(公告)日:2018-04-12
申请号:US15566290
申请日:2016-04-15
发明人: Hiroshi KUNUGI , Emiko AIZAWA , Hirokazu TSUJI
IPC分类号: C12Q1/06 , C12Q1/10 , C12Q1/14 , G01N33/487 , G01N33/15
CPC分类号: C12Q1/06 , A61K45/00 , C12N1/20 , C12Q1/10 , C12Q1/14 , C12Q1/68 , C12Q1/6883 , C12Q1/689 , G01N33/15 , G01N33/48735 , G01N33/56911 , G01N33/56916 , G01N2800/065 , G01N2800/302 , G01N2800/304
摘要: A marker for determining a mental disease is provided. The marker can be used in an objective diagnosis of such a mental disease. The marker contains one or more enterobacteria of Bifidobacterium, Lactobacillus, Lactobacillus brevis, Lactobacillus reuteri subgroup, Lactobacillus sakei subgroup, Atopobium cluster, Bacteroides fragilis group, Enterococcus, Clostridium coccoides group, Clostridium leptum subgroup, Staphylococcus, Clostridium perfringens, and Enterobacteriaceae.
-
-
-
-
-
-
-
-
-